ClinicalTrials.gg
RecruitingNCT07497165Updated Mar 27, 2026

Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma

An observational study in Relapsed/Refractory Multiple Myeloma (RRMM) and Multiple Myeloma, sponsored by Shanxi Bethune Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Shanxi Bethune Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
48
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
37th of 41
48 · median 210
Started
2025
with 54 others
Observational
41 of 448
28 open now
Primary completion
2026-11
later than 106 of 274 live
Registered
411th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 37th largest by planned enrollment of the 41 observational ones that give a count, is one of 55 that started in 2025, is one of 41 observational ones, reaches primary completion later than 106 of the 274 other live ones, and was the 411th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

Background:

Multiple Myeloma remains an incurable hematologic malignancy, and outcomes for relapsed/refractory multiple myeloma (RRMM) remain unsatisfactory despite advances in therapy. This study aims to evaluate the efficacy and safety of Epunamin combined with a DECP-based regimen in a real-world clinical setting.

Methods:

This multicenter, single-arm, real-world observational study will enroll 48 patients aged 18-75 years with RRMM diagnosed according to revised IMWG criteria who have received at least one prior systemic treatment. Eligible patients must have an ECOG performance status of 0-3, adequate treatment compliance, and written informed consent.

Key exclusion criteria include severe cardiac, pulmonary, hepatic, or renal dysfunction; unresolved prior treatment toxicity above grade 1; grade ≥2 peripheral neuropathy or grade 1 with pain; severe infection within 14 days; plasma cell leukemia; psychiatric disorders affecting compliance; pregnancy or lactation; recent other malignancies; hypersensitivity to study drugs; HIV infection; participation in another clinical trial within 30 days; or any condition deemed unsuitable by investigators.

Endpoints:

The primary endpoint is overall response rate (ORR) after four treatment cycles. Secondary endpoints include very good partial response (VGPR), complete response (CR), stringent complete response (sCR), minimal residual disease (MRD), duration of response (DOR), and time to next treatment (TTNT), assessed according to revised IMWG criteria.

Statistical Analysis:

Continuous variables will be summarized using mean, median, standard deviation, minimum, and maximum values. Normally distributed data will be analyzed using Student's t-test or ANOVA, while non-normally distributed data will use rank-sum tests. Categorical variables will be analyzed using chi-square or Fisher's exact tests, and ordinal variables by Ridit analysis or nonparametric tests. Survival outcomes including progression-free survival (PFS) and overall survival (OS) will be estimated using Kaplan-Meier analysis and compared by log-rank test. A two-sided P value \<0.05 will be considered statistically significant.

Study Period:

October 2025 to September 2027.

Read the detailed description

Background:

Multiple Myeloma remains an incurable plasma cell malignancy, and patients with relapsed/refractory disease continue to face limited therapeutic options and poor clinical outcomes. Epunamin, in combination with a DECP-based regimen, may provide a novel therapeutic strategy in this setting. However, evidence from real-world clinical practice remains limited.

Methods:

This is a multicenter, single-arm, real-world observational clinical study designed to evaluate the efficacy and safety of Epunamin combined with a DECP-based regimen in patients with relapsed/refractory multiple myeloma (RRMM). A total of 48 eligible patients aged 18-75 years who meet the revised International Myeloma Working Group diagnostic criteria and have received at least one prior systemic therapy will be enrolled. Eligible participants must have an Eastern Cooperative Oncology Group performance status of 0-3 and provide written informed consent.

Major exclusion criteria include severe cardiac, pulmonary, hepatic, or renal dysfunction; unresolved toxicities from prior chemotherapy; grade ≥2 peripheral neuropathy; active severe infection; plasma cell leukemia; concurrent malignancies diagnosed within 2 years; HIV infection; pregnancy or lactation; and known hypersensitivity to study drugs.

Endpoints:

The primary endpoint is overall response rate (ORR) after completion of four treatment cycles. Secondary endpoints include very good partial response (VGPR), complete response (CR), stringent complete response (sCR), minimal residual disease (MRD), duration of response (DOR), and time to next treatment (TTNT), based on laboratory findings and revised IMWG criteria.

Statistical Analysis:

Continuous variables will be summarized using mean, median, standard deviation, minimum, and maximum values. Categorical variables will be presented as counts and percentages. Normally distributed continuous variables will be analyzed using Student's t-test or analysis of variance, while non-normally distributed variables will be compared using rank-sum tests. Categorical variables will be analyzed using the chi-square test or Fisher's exact test. Ordinal variables will be assessed using Ridit analysis or nonparametric rank-sum tests. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), will be estimated using the Kaplan-Meier method, with comparisons performed using the log-rank test. All statistical analyses will be two-sided, with P \< 0.05 considered statistically significant.

Study Period:

Patient enrollment and follow-up are planned from October 2025 to September 2027.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma (RRMM)
  • Multiple Myeloma

Browse trials for

Keywords

  • Epunamin
  • DECP-Based Regimen
  • Multiple Myeloma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

relapsed/refractory Multiple Myeloma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 18 to 75 years with Multiple Myeloma diagnosed according to revised IMWG criteria.

Received at least one prior systemic treatment regimen. Performance Status score of 0-3. Able to understand treatment-related changes and management options during therapy and follow-up, with good treatment adherence and follow-up compliance.

Provided written . -

Exclusion criteria

Exclusion Criteria:

Severe dysfunction of major organs, including cardiac, pulmonary, hepatic, or renal impairment, defined as \<50%, diffusion capacity for carbon monoxide \<50% of predicted value due to chronic respiratory disease, serum >2 mg/dL, or aspartate aminotransferase >2.5 × , or estimated \<30 mL/min.

Toxicities from prior chemotherapy not recovered to baseline or grade ≤1. Peripheral neuropathy grade ≥2, or grade 1 with pain. Major surgery, radiotherapy, infection requiring systemic antibiotic treatment, or other severe infection within 14 days before enrollment.

High-risk plasma cell leukemia with peripheral blood plasma cells ≥20%. Psychiatric disorders, cognitive impairment, or other conditions affecting self-control or study compliance.

Pregnant or breastfeeding women, or fertile patients unwilling to use adequate during the study. Male patients unwilling to use effective contraception or refrain from sperm donation during treatment and for 3 months after the last dose.

Diagnosis or treatment of another within 2 years before enrollment. Known to Epunamin, Dexamethasone, Cisplatin, Etoposide, or Cyclophosphamide.

Infection positive. Participation in another clinical trial within 30 days before enrollment or during the study period.

Any condition considered unsuitable for participation by the investigator.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
48 participants (estimated)
Target follow-up
17 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients Receiving Epunamin Combined With DECP-Based Regimen

    Patients with relapsed/refractory Multiple Myeloma will receive Epunamin in combination with a DECP-based regimen as follows: Epunamin 10 mg/kg administered on days 1-5, or days 1-3 and days 15-17 Cisplatin 10 mg/m² on days 1-4 Etoposide 40 mg/m² on days 1-4 Cyclophosphamide 300 mg/m² on days 1-4 Dexamethasone 20-40 mg on days 1-4 Each treatment cycle lasts 28 days. Patients achieving clinical benefit will receive at least 4-6 cycles of treatment. For first administration, Epunamin will be introduced using a step-up dosing strategy, particularly in patients with high tumor burden or extramedullary bulky disease. The DECP regimen will start at 1/2 to 2/3 of the standard dose, and in patients older than 70 years, treatment will begin at 1/2 dose.During treatment, thromboprophylaxis with low-molecular-weight heparin or Rivaroxaban will be administered to prevent thrombotic events.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) is defined as the proportion of evaluable patients who achieve complete response (CR) or partial response (PR) after treatment.

    Formal efficacy evaluation will be performed at the end of cycle 4. M-protein and related laboratory parameters will be monitored during each treatment cycle, while bone marrow examination and serum free light chain assessment will be performed every 2 cycles to evaluate depth of response.

    Time frame: At the end of cycle 4 (approximately 4 months) Description

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gamie Z, Kapriniotis K, Papanikolaou D, Haagensen E, Da Conceicao Ribeiro R, Dalgarno K, Krippner-Heidenreich A, Gerrand C, Tsiridis E, Rankin KS. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data. Cancer Lett. 2017 Nov 28;409:66-80. doi: 10.1016/j.canlet.2017.08.036. Epub 2017 Sep 6. PubMed 28888998 ↗
  • NCCN Guidelines Version 3.2024 Multiple Myeloma[M].2024
  • Xia Z, Leng Y, Fang B, Liang Y, Li W, Fu C, Yang L, Ke X, Jiang H, Weng J, Liu L, Zhao Y, Zhang X, Huang Z, Liu A, Shi Q, Gao Y, Chen X, Pan L, Cai Z, Wang Z, Wang Y, Fan Y, Hou M, Ma Y, Hu J, Liu J, Zhou J, Zhang X, Meng H, Lu X, Li F, Ren H, Huang B, Shao Z, Zhou H, Hu Y, Yang S, Zheng X, Wei P, Pang H, Yu W, Liu Y, Gao S, Yan L, Ma Y, Jing H, Du J, Ling W, Zhang J, Sui W, Wang F, Li X, Chen W. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial. BMC Cancer. 2023 Oct 14;23(1):980. doi: 10.1186/s12885-023-11489-8. PubMed 37838670 ↗
  • Globocan, The Global Cancer Observatory (GCO) (2020a) Cancer Today; World Fact Sheets. 2020.
  • Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022 Aug;97(8):1086-1107. doi: 10.1002/ajh.26590. Epub 2022 May 23. PubMed 35560063 ↗

Individual participant data

Plan to share: Undecided — IPD sharing is not planned because the collected data contain sensitive clinical information, and data access is restricted in accordance with institutional policies and patient confidentiality requirements.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 173 non-industry observational studies under Multiple Myeloma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 31. This study's planned 12 months is below that.

Counting every sponsor, half of 239 studies reached it within 57 months; a quarter within 30 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 27, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Jun 30, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07497165
Lead sponsor
Shanxi Bethune Hospital
Responsible party
Weiwei Tian (Chief of Department, Shanxi Bethune Hospital) — Principal investigator
First posted
Mar 27, 2026
Start date
Nov 1, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Tian Weiwei Tian Weiwei, PhD
Contact
tianweiwei@yesh.net
+156-13485304136

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion